title: 18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case-series and literature review.
abstract: OBJECTIVE
  To describe FDG-PET/CT in amyloid light-chain (AL) amyloidosis.
  
  
  METHODS
  We describe a French multicenter study which included patients with AL amyloidosis who had undergone a FDG-PET/CT during follow-up.
  
  
  RESULTS
  Ten patients with AL amyloidosis (median age 62 years [59-85]) were analyzed. AL amyloidosis was of λ-type in 7/10 cases (70%) and localized amyloidosis in 4/10 cases (40%). AL amyloidosis was primary in 7/10 (70%) cases and associated with Waldenstrom's macroglobulinemia (n = 2) and plasmocytoma (n = 1) in the remaining cases. Median delay between diagnosis and PET was 1 month [0-51]. PET was positive in seven (70%) patients and showed a median FDG SUV of 6.5 [ 4-15 ]. FDG uptakes with positive PET were localized in seven patients, namely in the nasopharynx (n = 3), bronchopulmonary (n = 2), duodenal, cutaneous, bone, joint and muscular areas (n = 1, each). FDG uptakes on PET were concordant with the known organ impairment in 6/7 cases (86%) and showed unknown nasopharyngeal and mesenteric localization in one case each. PET was negative in the patient with cardiac amyloidosis and two patients with pulmonary amyloidosis.
  
  
  CONCLUSIONS
  High FDG uptake may be present in patients with AL amyloidosis, however prospective studies are needed in order to determine the place of FDG PET in AL amyloidosis.
authors.affiliation: Service de médecine interne, AP-HP, Hôpital Jean Verdier, Université Paris, Bondy, France. arsene.mekinian@jvr.aphp.fr
authors.forename: Arsene
authors.initials: A
authors.lastname: Mekinian
authors.forename: Arnaud
authors.initials: A
authors.lastname: Jaccard
authors.forename: Michael
authors.initials: M
authors.lastname: Soussan
authors.forename: David
authors.initials: D
authors.lastname: Launay
authors.forename: Sabine
authors.initials: S
authors.lastname: Berthier
authors.forename: Laure
authors.initials: L
authors.lastname: Federici
authors.forename: Guillaume
authors.initials: G
authors.lastname: Lefèvre
authors.forename: Dominique
authors.initials: D
authors.lastname: Valeyre
authors.forename: Robin
authors.initials: R
authors.lastname: Dhote
authors.forename: Olivier
authors.initials: O
authors.lastname: Fain
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000682:Amyloid / Q000378:metabolism*; D000686:Amyloidosis / Q000000981:diagnostic imaging* / Q000378:metabolism; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology; D008171:Lung Diseases / Q000000981:diagnostic imaging* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
chemical_list: D000682:Amyloid; D019275:Radiopharmaceuticals; C518669:amyloid L, human; D019788:Fluorodeoxyglucose F18